MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

MDT

87.03

+1.02%↑

121.11

+2.51%↑

VEEV

169.3

-0.38%↓

HQY

85.29

+1.85%↑

NEOG

9.65

+3.99%↑

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Open

SectorHealthcare

7.46 1.77

Buy Sell

Overview

Share price change

24h

Current

Min

7.17

Max

7.48

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	12.41 63.808
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-30.94% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	27M 385M
Previous open	5.69
Previous close	7.46

News Sentiment

By Acuity

50%

162 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

16 kwi 2026, 23:26 UTC

Hot Stocks

Stocks to Watch: Netflix, Alcoa, Knight-Swift, NiSource

16 kwi 2026, 20:41 UTC

Major Market Movers

Netflix Shares Slide After 2Q Outlook Misses Wall Street's Expectations

16 kwi 2026, 23:49 UTC

Market Talk

Amplitude's Pivot to Oil-Linked Supply Deal Catches Bull's Eye -- Market Talk

16 kwi 2026, 23:45 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

16 kwi 2026, 23:33 UTC

Market Talk

Major News Events

Gold Edges Higher on Hopes for U.S.-Iran Deal -- Market Talk

16 kwi 2026, 22:51 UTC

Market Talk

Netflix Sees Signs That Podcasts May Boost Engagement -- Market Talk

16 kwi 2026, 22:08 UTC

Earnings

Netflix Chair Reed Hastings to Leave Board in June -- 3rd Update

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Earnings From Discontinued Ops in 1Q Expected to Be Positively Impacted by Unaudited Gain on Disposal of Eagle Mine, Totaling Approximately $4M >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Pre-Announces Items Impacting 1Q Results

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Items of Significant Impact in 1Q Expected to Include Unaudited Realized Losses on Derivative Contracts of Approximately $13M, Primarily Related to Gold Collar Contracts >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Rev in 1Q Expected to Be Positively Impacted by Unaudited Provisional Pricing Adjustments on Prior-Period Concentrate Sales of Approximately $22M on Pre-Tax Basis >LUN.T

16 kwi 2026, 22:06 UTC

Earnings

Lundin Mining: Adjustments Primarily Include Upward Adjustments in Relation to Prior-Period Metal Sales >LUN.T

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Tech, Media & Telecom Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Major News Events

Basic Materials Roundup: Market Talk

16 kwi 2026, 20:50 UTC

Market Talk

Earnings

Health Care Roundup: Market Talk

16 kwi 2026, 20:49 UTC

Earnings

SpaceX Is Ready to Go Public. The Stock Market Is Its Rocket. -- Barrons.com

16 kwi 2026, 20:43 UTC

Earnings

Update: Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

16 kwi 2026, 20:40 UTC

Market Talk

Earnings

Netflix Says Engagement Quality Hits New High -- Market Talk

16 kwi 2026, 20:30 UTC

Hot Stocks

Stocks to Watch: TSMC, Abbott Laboratories, Nvidia, Netflix -- WSJ

16 kwi 2026, 20:25 UTC

Earnings

Netflix Stock Falls on Weak Guidance. Founder Reed Hastings Is Leaving the Board. -- Barrons.com

16 kwi 2026, 20:23 UTC

Earnings

These Stocks Are Today's Movers: AMD, Intel, TSMC, Abbott, Hims, Corning, Schwab, Polaris, and More -- Barrons.com

16 kwi 2026, 20:19 UTC

Earnings

Netflix Guidance Disappoints. The Stock Is Down. -- Barrons.com

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Alumina Costs in the Aluminum Segment Are Expected to Be Favorable by Approximately $20M Sequentially >AA

16 kwi 2026, 20:17 UTC

Earnings

Alcoa: Based on Higher LME and Midwest Premium Pricing and Expected Higher Shipments, Section 232 Tariff Costs on U.S. Imports of Aluminum From Canada Expected to Increase $35M Sequentially >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments Ranging Between 2.4M and 2.6M Metric Tons, and Between 2.6M and 2.8M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Aluminum Segment Production and Shipments to Remain Unchanged From Its Prior Projection >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments Ranging Between 9.7M to 9.9M Metric Tons, and Between 11.8M and 12.0M Metric Tons, Respectively >AA

16 kwi 2026, 20:16 UTC

Earnings

Alcoa: Expects 2026 Total Alumina Segment Production and Shipments to Remain Unchanged From Prior Projection >AA

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-30.94% downside

12 Months Forecast

Average 5 USD -30.94%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

162 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.